BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/22/2022 6:17:12 AM | Browse: 448 | Download: 874
 |
Received |
|
2021-02-28 10:32 |
|
Peer-Review Started |
|
2021-02-28 10:46 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-09-02 02:08 |
|
Revised |
|
2021-09-16 11:33 |
|
Second Decision |
|
2021-12-10 06:13 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-12-11 03:41 |
|
Articles in Press |
|
2021-12-11 03:41 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-01-17 13:17 |
|
Publish the Manuscript Online |
|
2022-01-22 06:17 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Maja Popovic, Gorana Matovina-Brko, Masa Jovic and Lazar S Popovic |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Lazar S Popovic, MD, PhD, Professor, Department for Medical Oncology, Oncology Institute of Vojvodina, University of Novi Sad, Department for Medical Oncology, Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad 21000, Serbia. <email>lazar.popovic@mf.uns.ac.rs</email>, Sremska Kamenica 21204, Serbia. lazar.popovic@mf.uns.ac.rs |
| Key Words |
Renal cell carcinoma; Immunotherapy; Checkpoint inhibitors; Biomarkers; Tumor microenvironment; Programmed cell death 1 receptor |
| Core Tip |
Renal cell cancer is a highly immunogenic tumor infiltrated by cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved (immunotherapy and immunotherapy/TKI) as first-line treatment for mccRCC. |
| Publish Date |
2022-01-22 06:17 |
| Citation |
Popovic M, Matovina-Brko G, Jovic M, Popovic LS. Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma. World J Clin Oncol 2022; 13(1): 28-38 |
| URL |
https://www.wjgnet.com/2218-4333/full/v13/i1/28.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v13.i1.28 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
